Skip to content
Screener

ADMA Biologics ADMA Income Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
$124.4M+2.0%$114.49M-0.3%$139.16M+18.4%$134.22M+12.0%$121.98M+13.8%
$38.12M-30.4%$33.74M-37.2%$50.35M-7.1%$58.6M-2.6%$54.76M+10.1%
$86.28M+28.3%$80.75M+32.2%$88.82M+40.2%$75.63M+26.8%$67.23M+17.0%
69.4%+14.2pp70.5%+17.3pp63.8%+9.9pp56.3%+6.6pp55.1%+1.5pp
$6.01M+483%$2.6M+214%$1.38M+252%$1.53M+271%$1.03M+84.1%
$26.74M+20.4%$26.74M+11.1%$23.51M+0.8%$21.78M+17.3%$22.21M+33.8%
$775K+14.8%$775K+14.8%$775K+14.8%
$33.83M+38.5%$22.48M-14.3%$26.07M+4.2%$24.61M+22.9%$24.43M+33.8%
$52.45M+22.5%$58.27M+67.1%$62.75M+63.7%$51.01M+28.7%$42.8M+9.2%
42.2%+7.1pp50.9%+20.5pp45.1%+12.5pp38%+4.9pp35.1%-1.5pp
$3.42M+86.7%$2.1M+6.3%$1.63M-43.5%$1.68M-52.1%$1.83M-51.5%
-$2.21M+18.3%-$1.15M+19.8%-$1.16M+68.0%-$3.5M-21.0%-$2.7M+19.4%
$50.24M+25.3%$57.13M+70.8%$61.6M+77.4%$47.52M+29.3%$40.1M+11.8%
$12.42M+111%$11.8M+80.2%$12.22M+116%$11.09M+1,220%$5.88M+55.1%
$37.82M+10.5%$45.33M+68.5%$49.38M-55.9%$36.43M+1.4%$34.22M+6.7%
30.4%+2.4pp39.6%+16.2pp35.5%-59.7pp27.1%-2.8pp28.1%-1.9pp
$0.16+14.3%$0.19+72.7%$0.20-56.5%$0.150.0%$0.14+7.7%
$54.15M+20.9%$60.07M+63.3%$64.75M+60.6%$53.01M+27.6%$44.8M+9.0%
43.5%+6.8pp52.5%+20.4pp46.5%+12.2pp39.5%+4.8pp36.7%-1.6pp
$52.45M+22.5%$58.27M+67.1%$62.75M+63.7%$51.01M+28.7%$42.8M+9.2%

FAQ

What is ADMA Biologics's revenue?
ADMA Biologics (ADMA) generated $512.3M in revenue over the trailing twelve months, up 8.0% year over year.
Is ADMA Biologics profitable?
ADMA Biologics reported $169.0M in net income over the trailing twelve months, a 33.0% net margin.
What are ADMA Biologics's profit margins?
Gross margin is 64.7% and operating margin is 43.8%, with a 33.0% net margin.
What is ADMA Biologics's earnings per share?
ADMA Biologics's diluted EPS over the trailing twelve months is $0.70.
Where does ADMA Biologics's income statement data come from?
Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.